Figure 5.

The levels of serum c‐miR‐16 (A), c‐miR‐21 (B), c‐miR‐155 (C), and c‐miR‐195 (D) compared between healthy controls (n = 15) and breast cancer patients with different molecular subtypes: HER‐2 over‐expression (n = 7), Luminal A (n = 4), Luminal B (n = 27), and triple negative breast cancer (n = 2). HER‐2 OE, HER‐2 over‐expression breast cancer patients; LA, breast cancer patients with Luminal A subtype; LB, breast cancer patients with Luminal B subtype; TN, triple negative breast cancer patients. The F test and Student's t test were performed for comparisons between groups